Dr George Varughese


Dr George I Varughese FRCPI; FRCP (UK)

Year qualified: 1997

Languages spoken: English, Malayalam

GMC: 4783169


Dr Varughese was appointed as Consultant Physician at the University Hospital of North Midlands (Staffordshire) NHS Trust in 2008. He qualified in 1997 and has been working in the NHS since 1998 through various medical sub-specialty rotations as a junior doctor in the Midlands and after completing the MRCP examinations conducted by the Royal College of Physicians of Ireland and the UK, he trained in Diabetes, Endocrinology & General (Internal) Medicine on the West Midlands higher specialist training programme obtaining CCT in 2008 in these specialties from the JRCPTB. He has been instrumental in service development of various sub-specialist areas in the specialties of Diabetes and Endocrinology at UHNM and has collaborated with other regional centres.

He was awarded the Nye Bevan NHS Executive Leadership award from the NHS Leadership Academy in 2016. A significant proportion of his outpatient workload involves treating patients with Diabetes and Endocrine disorders and in conjunction he also looks after inpatients in General (Internal) Medicine presenting with multiple pathologies. He is also involved with undergraduate and postgraduate medical training and is a Royal College of Physicians examiner and SWG member for the MRCP PACES exam. He is a member of Diabetes UK, Society for Endocrinology (UK) and also a Fellow of the RCP London.

Dr Varughese treats adult patients with adrenal, thyroid, parathyroid, pituitary disease and metabolic disorders related to sodium and calcium electrolyte imbalance as well as type 1 and type 2 diabetes mellitus focusing on microvascular and macrovascular complications to cardiovascular risk reduction strategies. He has a widespread publication record that extends over a number of fields in Diabetes and Endocrinology as well as General (Internal) Medicine.


Original Papers:

  1. Hyperthyroidism and Graves’ disease: Is an ultrasound examination needed. Ind J Endocrinol Metab 2016 Nov-Dec;20(6):866-869
  2. Can a baseline morning cortisol predict outcome of short Synacthen test in an endocrine unit in an outpatient setting. Clin Endocrinol (Oxf) 2015 Feb;82(2):309-11
  3. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diab Res Clin Pract 2014 Mar;103(3):p37-9
  4. Bariatric surgery and diabetic retinopathy: a pilot analysis. Obes Surg 2012 Mar;22(3);515-6
  5. Medical student evaluation of clinical teaching sessions in diabetes and endocrinology: a quantitative analysis based on formatted feedback over 1 year. Diabet Med 2010 Nov;27(11):1329-31
  6. Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation. Heart 2007 Apr;93(4):495-9
  7. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007 Apr;261(4):384-91
  8. The prothrombotic risk of diabetes mellitus in atrial fibrillation and heart failure. J Thromb Haemost 2005 Dec;3(12):2811-3

Case Reports:

  1. Cushing’s disease: Establishing the Diagnosis and Management Approach. J Assoc Phys In 2013 Apr;61:278-80
  2. Random serum cortisol levels and short synacthen testing. Int J Clin Pract 2010 Jan;64(1):124-6
  3. Carbimazole therapy in the setting of end-stage renal disease and haemodialysis. Nephrol Dial Transplant 2006 Aug;21(8):2318-9
  4. Caveats in treating thyroid disease: practical implications. J R Soc Med 2006 Nov;99(11):582-3


  1. The challenges of emerging adulthood – transition from paediatric to adult diabetes. World J Diab 2014 Oct 15;5(5):630-5
  2. Metformin, heart failure and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007 Sep 8;335(7618):508-12